Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1992)
  2. Solid Tumor Oncology Division (1623)
  3. GSK Faculty (765)
  4. Survivorship Research (637)
  5. Population Sciences Research Program (614)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (414)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2106)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (90)
  5. Editorial (83)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1992)
  2. Solid Tumor Oncology Division (1623)
  3. GSK Faculty (765)
  4. Survivorship Research (637)
  5. Population Sciences Research Program (614)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (101)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (846)
  3. JNCI: Journal of the National Cancer Institute (484)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (138)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4648)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Safety and efficacy of etigilimab (anti-TIGIT) with nivolumab (anti-PD1) in recurrent/advanced solid tumors
    Meeting Abstract

    McKean, M.; Dumbrava, E. E.; Hamid, O.; Merriam, P.; Call, J. A.; Feely, W.; Green, A.; Vaishampayan, U. N.; Moore, K. N.; Weroha, S.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Relapse free survival (RFS) at 3 years by pathological (path) response to neoadjuvant systemic treatment (NST) in patients (pts) with surgically resectable, high-risk melanoma
    Meeting Abstract

    Burton, E.; Milton, D.; Simpson, L.; Tetzlaff, M.; Glitza, I. C.; Ross, M. I.; Gershenwald, J. E.; McQuade, J.; Wong, M.; Patel, S.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • The effect of LNS8801 in combination with pembrolizumab in patients with treatment-refractory cutaneous melanoma
    Meeting Abstract

    Rodon, J.; Chaney, M. F.; Cohen, J.; Garyantes, T. K.; Ishizuka, J.; Lin, J. J.; Lorusso, P.; Mita, A.; Mita, M.; Muller, C.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • First-in-human phase I study of givastomig, a novel Claudin 18.2/4-1BB bispecific antibody in advanced solid tumors
    Meeting Abstract

    Ku, G.; Shen, L.; Klempner, S. J.; Pan, H.; Kratz, J.; Liang, X.; Deng, Y.; Kim, S.; Wang, Z.; Feller, L.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • AL101 therapy in patients with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC): Final ACCURACY trial results and meta-analysis of clinical outcomes
    Meeting Abstract

    Ferrarotto, R.; Bobbili, P.; Bowles, D. W.; Even, C.; Gordon, G.; Gutierrez, A.; Metcalf, R.; Muzaffar, J.; Nguyen, C.; Oliva, M.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • HB-200 arenavirus-based immunotherapy plus pembrolizumab as a first-line treatment of patients with recurrent/metastatic HPV16 positive head and neck cancer
    Meeting Abstract

    Nabell, L.; Ho, A. L.; Posner, M. R.; Neupane, P.; Naqash, A. R.; Wong, S.; Niu, J. J.; Pearson, A. T.; Laux, D.; Adkins, D. R.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Dose expansion results of the bifunctional EGFR/TGFb inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma
    Meeting Abstract

    Hanna, G. J.; Kaczmar, J.; Zandberg, D. P.; Wong, D. J.; Yilmaz, E.; Sherman, E. J.; Calvo, A. H.; Sacco, A. G.; Bohr, D.; Reiners, R.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Clinical and translational data from the phase I SURPASS trial of ADP-A2M4CD8 T cell receptor (TCR) T cell therapy alone or combined with nivolumab in solid tumors
    Meeting Abstract

    Garcia, V. M.; Calvo, E.; Asch, A.; Butler, M.; Zugazagoitia, J.; Charlson, J.; Cervantes, A.; Van Tine, B.; Aggen, D.; Clarke, J.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Phase I study of ceralasertib (cerala) in combination with AZD5305 in patients (pts) with advanced/metastatic ovarian cancer (OC) previously treated with PARP inhibitors (PARPis)
    Meeting Abstract

    Shapiro, G. I.; Basu, B.; El-Khoueiry, A. B.; Postel-Vinay, S.; Im, S. A.; Rha, S. Y.; Friedman, C. F.; Italiano, A.; Kim, Y. M.; Lim, M. C.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Isolation of cell-free DNA of patients with mucosa-associated lymphoid tissue (MALT) lymphoma
    Meeting Abstract

    Berger, J. M.; Kienzle, A.; Hatziioannou, T.; Tomasich, E.; Mayerhoefer, M.; Kiesewetter-Wiederkehr, B.; Berghoff, A. S.; Preusser, M.; Raderer, M.
    Annals of Oncology (2023)

    Fulltext@MSK | Save